OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative ocular therapies, announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. The company specializes in treatments for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition without FDA-approved therapy.
OKYO's management will deliver a pre-recorded presentation available on-demand from 7:00 am EDT on the conference day. Interested parties can register for the conference and arrange virtual 1x1 meetings with OKYO's management through H.C. Wainwright representatives.
OKYO Pharma (NASDAQ: OKYO), una compagnia biofarmaceutica in fase clinica specializzata nello sviluppo di terapie oculari innovative, ha annunciato la sua partecipazione alla 4ª Conferenza Virtuale Annuale di Oftalmologia H.C. Wainwright che si terrà il 15 agosto 2024. L'azienda è specializzata nel trattamento della malattia infiammatoria dell'occhio secco (DED), un mercato da miliardi di dollari, e nel dolore corneale neuropatico (NCP), una condizione oculare priva di terapia approvata dalla FDA.
Il management di OKYO presenterà una registrazione pre-registrata disponibile on-demand a partire dalle 7:00 am EDT del giorno della conferenza. Le parti interessate possono registrarsi per la conferenza e organizzare incontri virtuali 1x1 con il management di OKYO tramite i rappresentanti di H.C. Wainwright.
OKYO Pharma (NASDAQ: OKYO), una compañía biofarmacéutica en etapa clínica centrada en desarrollar terapias oculares innovadoras, anunció su participación en la 4ª Conferencia Virtual Anual de Oftalmología H.C. Wainwright el 15 de agosto de 2024. La empresa se especializa en tratamientos para la enfermedad inflamatoria del ojo seco (DED), un mercado de miles de millones de dólares, y el dolor corneal neuropático (NCP), una condición ocular sin terapia aprobada por la FDA.
La dirección de OKYO realizará una presentación pregrabada que estará disponible bajo demanda a partir de las 7:00 am EDT el día de la conferencia. Las partes interesadas pueden registrarse para la conferencia y organizar reuniones virtuales 1x1 con la dirección de OKYO a través de los representantes de H.C. Wainwright.
OKYO Pharma (NASDAQ: OKYO), 혁신적인 안과 치료제를 개발하는 데 중점을 둔 임상 단계의 바이오 제약 회사가 2024년 8월 15일 H.C. Wainwright 제4회 연례 안과 가상 회의에 참여한다고 발표했습니다. 이 회사는 염증성 건성안 질환 (DED), 수십억 달러 규모의 시장에 대한 치료제 및 신경병증성 각막 통증 (NCP), FDA 승인 치료제가 없는 안과적 상태에 전문화되어 있습니다.
OKYO의 경영진은 회의 당일 오전 7:00 EDT부터 주문형으로 사용 가능한 사전 녹화된 프레젠테이션을 제공합니다. 관심자들은 회의에 등록하고 H.C. Wainwright 대표를 통해 OKYO의 경영진과 가상 1x1 회의를 조정할 수 있습니다.
OKYO Pharma (NASDAQ: OKYO), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies oculaires novatrices, a annoncé sa participation à la 4ème Conférence Virtuelle Annuelle d'Ophtalmologie H.C. Wainwright le 15 août 2024. L'entreprise se spécialise dans les traitements pour la maladie inflammatoire de l'œil sec (DED), un marché de plusieurs milliards de dollars, et la douleur cornéenne neuropathique (NCP), une condition oculaire sans thérapie approuvée par la FDA.
La direction d'OKYO fera une présentation préenregistrée disponible à la demande à partir de 7h00 EDT le jour de la conférence. Les parties intéressées peuvent s'inscrire à la conférence et organiser des réunions virtuelles individuelles avec la direction d'OKYO par l'intermédiaire des représentants de H.C. Wainwright.
OKYO Pharma (NASDAQ: OKYO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung innovativer okulärer Therapien konzentriert, gab seine Teilnahme an der 4. Jährlichen Virtuellen Ophthalmologie-Konferenz von H.C. Wainwright am 15. August 2024 bekannt. Das Unternehmen spezialisiert sich auf Behandlungen für entzündliche Erkrankungen des trockenen Auges (DED), einen Markt von Milliardenhöhe, sowie auf neuropathische Hornhaut-Schmerzen (NCP), eine okuläre Erkrankung ohne von der FDA genehmigte Therapie.
Das Management von OKYO wird eine vorab aufgezeichnete Präsentation liefern, die am Konferenztag ab 7:00 Uhr EDT auf Abruf verfügbar ist. Interessenten können sich für die Konferenz anmelden und über die Vertreter von H.C. Wainwright virtuelle 1x1-Meetings mit dem Management von OKYO organisieren.
- Participation in a significant industry conference, potentially increasing visibility and investor interest
- Focus on multi-billion-dollar market of inflammatory dry eye disease (DED)
- Development of treatment for neuropathic corneal pain (NCP), an unmet medical need without FDA-approved therapy
- None.
LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the company will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, which is being held on Thursday, August 15th.
Management’s pre-recorded company presentation can be accessed on-demand beginning at 7:00 am EDT on the day of the conference.
For additional information, or to register for the conference, please click here. To arrange a virtual 1x1 meeting with OKYO Pharma’s management, please contact your H.C. Wainwright representative.
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
When is OKYO Pharma participating in the H.C. Wainwright Ophthalmology Conference?
What are the main therapeutic areas OKYO Pharma (NASDAQ: OKYO) is focusing on?
How can investors access OKYO Pharma's presentation at the H.C. Wainwright conference?
Is there an FDA-approved therapy for neuropathic corneal pain (NCP) that OKYO Pharma is developing?
